Abstract: Acute coronary syndrome is one of the major health problems worldwide and accounts for a great number of cardiac hos-pitalizations in the Western world. Atherosclerotic plaque rupture or erosion followed by platelet activation and total occlusion of a coronary artery is involved in the pathogenesis of acute coronary syndrome and myocardial infarction. The glycoprotein IIb/IIIa recep-tor, a platelet surface integrin, plays a key role in platelet aggregation once it has been activated. In order to improve myocardial tissue reperfusion, platelet inhibition with glycoprotein IIb/IIIa inhibitors (in combination with aspirin, clopidogrel, and heparin) has been shown as beneficial adjuvant therapy in patients with acute myocardial infarc...
A b s t r a c t Antiplatelet drugs play a crucial role in the treatment of patients with myocardial ...
The definitive version is available at www.blackwell-synergy.comSignificant advances in the treatmen...
Glycoprotein IIb/IIIa inhibitors are an adjuvant therapy for the treatment of patients with acute co...
textabstractPlatelet activation and aggregation has been shown to be heightened in the setting of ac...
Platelet activation and aggregation has been shown to be heightened in the setting of acute coronary...
Introduction: Glycoprotein IIb/IIIa receptor inhibitors reduce major adverse cardiovascularevents (M...
Introduction: Glycoprotein IIb/IIIa receptor inhibitors reduce major adverse cardiovascularevents (M...
The glycoprotein IIb/IIIa inhibitors (GPIs) represent a relatively new therapy for acute coronary sy...
Antiplatelet therapy is integral to the acute and long-term management of acute coronary syndromes (...
Platelet activation and aggregation has been shown to be heightened in the setting of acute coronar...
Objective: To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antag...
Objective: To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antag...
Objective: To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antag...
Background: Antiplatelet therapy is a cornerstone in coronary artery disease management. However, pa...
Background: Coronary artery disease has been increasing by epidemic proportions in this part of the ...
A b s t r a c t Antiplatelet drugs play a crucial role in the treatment of patients with myocardial ...
The definitive version is available at www.blackwell-synergy.comSignificant advances in the treatmen...
Glycoprotein IIb/IIIa inhibitors are an adjuvant therapy for the treatment of patients with acute co...
textabstractPlatelet activation and aggregation has been shown to be heightened in the setting of ac...
Platelet activation and aggregation has been shown to be heightened in the setting of acute coronary...
Introduction: Glycoprotein IIb/IIIa receptor inhibitors reduce major adverse cardiovascularevents (M...
Introduction: Glycoprotein IIb/IIIa receptor inhibitors reduce major adverse cardiovascularevents (M...
The glycoprotein IIb/IIIa inhibitors (GPIs) represent a relatively new therapy for acute coronary sy...
Antiplatelet therapy is integral to the acute and long-term management of acute coronary syndromes (...
Platelet activation and aggregation has been shown to be heightened in the setting of acute coronar...
Objective: To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antag...
Objective: To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antag...
Objective: To assess the efficacy of tirofiban in comparison to usual care or other GPIIb/IIIa antag...
Background: Antiplatelet therapy is a cornerstone in coronary artery disease management. However, pa...
Background: Coronary artery disease has been increasing by epidemic proportions in this part of the ...
A b s t r a c t Antiplatelet drugs play a crucial role in the treatment of patients with myocardial ...
The definitive version is available at www.blackwell-synergy.comSignificant advances in the treatmen...
Glycoprotein IIb/IIIa inhibitors are an adjuvant therapy for the treatment of patients with acute co...